Study of exopolysaccharide produced by Streptomyces rochie strain OF1 and its effect as ameliorative on osteoarthritis in rats via inhibiting TNF-α/COX2 pathway

Mohamed, Sahar S.; Awady, Mohamed E. El; Abdelhamid, Sayeda Abdelrazek; Hamed, Ahmed A.; Salama, Abeer; Selim, Manal S.

doi:10.1186/s43141-023-00471-3

Cited by 7 publications

(5 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might have been as a result of a lower concentration used than would record signi cant biocontrol activity. A study reported by Mohamed et al [45] on exopolysaccharide (EPSS5) produced from Streptomyces rochie strain OF1 documented its middling antibiotic activity against strains of Escherichia coli ATCC 25922 and Staphylococcus aureus NRRLB-767 worked on. In addition, the exopolysaccharide exhibited little antibacterial activity against Klebsiella pneumoniae ATCC 10145 and methicillin-resistant Staphylococcus aureus strains used in their research.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Antibacterial Activity of Exopolysaccharide Produced from Pseudomonas aeruginosa strain S16 on Environmental and Clinical Bacteria

Okorie,

Ogunjobi

2023

Preprint

View full text Add to dashboard Cite

Environmental and clinical bacteria have developed resistance to the commonly available antibiotics, erstwhile produced to treat diseases caused by them. Indeed, antibiotic resistance has morphed into an issue of worldwide proportions in urgent need of effective remedies. The aim of this study was to assess the antibacterial activity of exopolysaccharide produced from stock culture of Pseudomonas aeruginosa strain S16 (accession number OQ734845), which had previously been isolated from soil in the environment, on selected identified environmental and clinical bacteria, which were both antibiotic-resistant and antibiotic-susceptible. Bacterial isolates were initially isolated from both soil and pig faecal matter using serial dilution and pour plate methods, before they were identified through biochemical tests. Screening tests for exopolysaccharide production in these isolates, had shown up S16 and F22 as the best producers of exopolysaccharide; identified as Pseudomonas aeruginosa strain S16 (accession number OQ734845) and Providencia vermicola strain F22 (accession number OQ734846), respectively. The latter was not a pseudomonad and was therefore excluded from the study. The antibacterial properties of the exopolysaccharide were then assessed using agar well diffusion assay and it was observed to be effective only against Staphylococcus aureus SO183 at 0.260 g/L and against identified Klebsiella pneumoniae only at 0.156 g/L.The positive controls used in the study were antibiotic discs containing the class of antibiotics susceptible to each selected identified bacterium. The exopolysaccharide from Pseudomonas aeruginosa strain S16, therefore, proved promising as an alternative antibiotic to the present failing antibiotics in common usage.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Antibacterial Activity of Exopolysaccharide Produced from Pseudomonas aeruginosa strain S16 on Environmental and Clinical Bacteria

Okorie,

Ogunjobi

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The major yield fraction obtained by 1 volume of absolute ethanol was dried under vacuum at 40 °C 59 . The UV absorption spectrum was recorded using a UV–Vis Spectrophotometer (2401PC Shimadzu, Japan) between 200 and 800 nm, to examine the existence of proteins and nucleic acids 3 . The main fraction of EPS from 1 volume ethanol (BMEPS) was assayed in-vitro against Acetylcholinesterase inhibition.…”

Section: Methodsmentioning

confidence: 99%

“…On the other hand, EPSs are frequently utilized as viscosifying, stabilizing, gelling, or emulsifying agents in the food industry because of their distinctive physical and rheological qualities 2 . Microbial polysaccharides are incorporated into new targets, such as bioflocculants, bio absorbents, heavy metal removal, and drug delivery agents 3 . Additionally, antitumor, antiviral, immunostimulatory, and anti-inflammatory actions are among the biological effects of EPSs 4 .…”

mentioning

confidence: 99%

Characterization and in-vitro Alzheimer’s properties of exopolysaccharide from Bacillus maritimus MSM1

Selim

Mohamed

Asker

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

Four bacterial isolates were obtained from marine sediments collected from Sahl Hashish, Hurghada Red Sea, Egypt. This study was designed to search for promising anti-Alzheimer natural polysaccharide; therefore, four isolates were screened for exopolysaccharides (EPSs) production and acetylcholinesterase inhibition. The isolate S16 provided the highest EPS yield (7.51 g/L) and acetylcholinesterase inhibition. It was identified morphologically and genetically using 16S rRNA gene sequence analysis as Bacillus maritimus. A Physicochemical analysis of S16 exopolysaccharide (BMEPS) was estimated, which pointed to the presence of uronic acid and sulfate (24.7% and 18.3%, respectively). HPLC analysis indicated that mannuronic acid, glucuronic acid, glucose, and mannose are presented in a molar ratio of 0.8:1.0:2.8:2.3, respectively. Furthermore, FT-IR revealed an abundance of β-configurations. The GPC estimated the average molecular weight (Mw) as 4.31 × 104 g/mol. BMEPS inhibited AChE (IC50; 691.77 ± 8.65 μg/ ml), BChE (IC50; 288.27 ± 10.50 μg/ ml), and tyrosinase (IC50; 3.34 ± 0.09, 14.00 ± 0.14, and 22.96 ± 1.23 μg/ ml during incubation durations of 10, 20, and 40 min). It also demonstrated a selective anti-inflammatory action against COX-2 rather than COX-1. Moreover, BMEPS exhibited antioxidant capabilities as free radical and oxygen reactive species (ROS) scavenger, metal chelator, reductant agent, and lipid peroxidation suppressor. These activities are due to the distinct chemical composition. The findings of this study indicate that BMEPS could be considered as promising anti-disease Alzheimer's (AD) material in an in-vitro model, which qualifies it for advanced in-vivo studies in the discovery of alternative Alzheimer’s treatment.

show abstract

“…The results showed that the Streptomyces strains that produced the anti-Candida derivatives came from the most diverse environments. These included 16 studies collecting strains from distinct soil sediment samples [43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58], 11 studies obtaining strains from lakes, seas and oceans [59][60][61][62][63][64][65][66][67][68][69][70], and 5 studies isolating them from marine sponges. Additionally, one study derived strains from marine corals [71], while insects such as wasps, ants and cockroaches contributed isolates in five studies [72][73][74][75][76].…”

Section: Streptomyces-derived Compounds With Anti-candida Activity De...mentioning

confidence: 99%

Streptomyces: a natural source of anti-Candida agents

Martins,

Rodrigues da Silva,

Ratcliffe

et al. 2023

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. There is an urgent need to source new compounds that can combat the current threat of serious infection caused by Candida spp. and contend with the problem of antimicrobial resistance. Gap. A synthesis of the evidence available from the current literature is needed to identify promising antifungal chemotherapeutics. Aim. To highlight anti-Candida compounds derived from Streptomyces spp. (a well-known source of antimicrobial compounds) that could translate to potential candidates for future clinical practice. Methodology. A comprehensive review was conducted across three scientific literature databases spanning a 13-year period. Results. We identified 151 compounds with anti-Candida activity. Amongst these, 40 were reported with very strong inhibitory activity, having minimum inhibitory concentrations (MICs) against Candida spp. of <3.5 µg ml−1, 66 compounds were considered strong inhibitors and 45 compounds exhibited moderate inhibitory potential. From an analysis of the MICs, we deduced that the actinomycin-like compounds RSP01 and RSP02 were probably the most promising anti-Candida compounds. Other antifungals of note included filipin-like compounds, which demonstrated superior inhibition to amphotericin B and activity against Candida glabrata and Candida krusei, and bafilomycin derivatives, which had substantial inhibition against Candida parapsilosis. Conclusion. It is essential to recognize the limitations inherent in the quest for new antifungals, which encompass toxicity, in vivo effectiveness and constraints associated with limited data access. However, further investigation through in-depth study and emerging technologies is of paramount importance, given that there are still many more compounds to discover. This review highlights the importance of antifungal compounds derived from Streptomyces , which demonstrate robust inhibition, and, in many cases, low toxicity, making them promising candidates for the development of novel antifungal agents.

show abstract

Study of exopolysaccharide produced by Streptomyces rochie strain OF1 and its effect as ameliorative on osteoarthritis in rats via inhibiting TNF-α/COX2 pathway

Cited by 7 publications

References 55 publications

Assessment of Antibacterial Activity of Exopolysaccharide Produced from Pseudomonas aeruginosa strain S16 on Environmental and Clinical Bacteria

Assessment of Antibacterial Activity of Exopolysaccharide Produced from Pseudomonas aeruginosa strain S16 on Environmental and Clinical Bacteria

Characterization and in-vitro Alzheimer’s properties of exopolysaccharide from Bacillus maritimus MSM1

Streptomyces: a natural source of anti-Candida agents

Contact Info

Product

Resources

About